Humana/$HUM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Humana
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Ticker
$HUM
Sector
Primary listing
NYSE
Employees
65,680
Headquarters
Website
Humana Metrics
BasicAdvanced
$33B
20.78
$13.04
0.44
$3.54
1.31%
Price and volume
Market cap
$33B
Beta
0.44
52-week high
$315.35
52-week low
$206.87
Average daily volume
2.2M
Dividend rate
$3.54
Financial strength
Current ratio
1.952
Quick ratio
1.522
Long term debt to equity
68.795
Total debt to equity
70.424
Dividend payout ratio (TTM)
27.22%
Interest coverage (TTM)
5.79%
Profitability
EBITDA (TTM)
4,015
Gross margin (TTM)
15.03%
Net profit margin (TTM)
1.28%
Operating margin (TTM)
3.06%
Effective tax rate (TTM)
24.88%
Revenue per employee (TTM)
$1,870,000
Management effectiveness
Return on assets (TTM)
4.69%
Return on equity (TTM)
9.03%
Valuation
Price to earnings (TTM)
20.781
Price to revenue (TTM)
0.265
Price to book
1.79
Price to tangible book (TTM)
4.51
Price to free cash flow (TTM)
13.391
Free cash flow yield (TTM)
7.47%
Free cash flow per share (TTM)
20.238
Dividend yield (TTM)
1.31%
Forward dividend yield
1.31%
Growth
Revenue change (TTM)
9.88%
Earnings per share change (TTM)
-6.80%
3-year revenue growth (CAGR)
10.80%
10-year revenue growth (CAGR)
8.97%
3-year earnings per share growth (CAGR)
-18.95%
10-year earnings per share growth (CAGR)
4.43%
3-year dividend per share growth (CAGR)
5.97%
10-year dividend per share growth (CAGR)
12.10%
What the Analysts think about Humana
Analyst ratings (Buy, Hold, Sell) for Humana stock.
Bulls say / Bears say
On July 30, 2025, Humana raised its full-year 2025 adjusted EPS guidance to approximately $17.00 and revenue guidance to at least $128 billion following stronger-than-expected Q2 results, reflecting confidence in its cost control and margin outlook (Reuters ).
In Q1 2025, Humana reported an adjusted EPS of $11.58, beating analysts’ estimates and achieving a medical cost ratio of 87.4%, underscoring effective cost management amid inflationary pressures (Reuters ).
Growth in Humana’s CenterWell primary care segment was cited by Reuters as a key driver of its improved first-half performance, helping to diversify revenue streams and strengthen its value-based care capabilities (Reuters ).
Humana was ordered by a federal court to pay over $32 million in legal fees to whistleblower attorneys under the False Claims Act, highlighting costly litigation risks and potential reputational damage (Reuters ).
A Texas federal judge dismissed Humana’s lawsuit challenging CMS’s lower star ratings for its Medicare Advantage plans, risking reduced quality bonus payments in 2026 and pressuring future profitability (Reuters ).
Despite strong financial results, Humana still anticipates a decline in individual Medicare Advantage memberships of up to 500,000 in 2025, indicating continued contraction in its core insurance business that may pressure revenue growth (Reuters ).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Humana Financial Performance
Revenues and expenses
Humana Earnings Performance
Company profitability
Humana News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Humana stock?
Humana (HUM) has a market cap of $33B as of October 15, 2025.
What is the P/E ratio for Humana stock?
The price to earnings (P/E) ratio for Humana (HUM) stock is 20.78 as of October 15, 2025.
Does Humana stock pay dividends?
Yes, the Humana (HUM) stock pays dividends to shareholders. As of October 15, 2025, the dividend rate is $3.54 and the yield is 1.31%. Humana has a payout ratio of 27.22% on a trailing twelve-month basis.
When is the next Humana dividend payment date?
The next Humana (HUM) dividend payment is scheduled for October 31, 2025.
What is the beta indicator for Humana?
Humana (HUM) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.